Search Within

Keith S Pentlow

Formats
  1. Journal Article (38)
  2. Meeting Abstract (27)
  3. Conference Paper (5)
Groups
  1. GSK Faculty (59)
  2. Molecular Imaging and Therapy Service (59)
  3. Radiology, Department of (59)
  4. Molecular Pharmacology and Chemistry Program Faculty (58)
  5. Sloan Kettering Institute Faculty (58)
  6. Medical Physics (35)

More Groups

People
  1. Steven Larson (57)
  2. Ronald Finn (35)
  3. John Humm (27)
  4. Martin Graham (15)
  5. Bradley Beattie (12)
  6. Farhad Daghighian (11)

More People

Years
  1. 2024 (1)
  2. 2023 (3)
  3. 2022 (2)
  4. 2021 (1)
  5. 2019 (2)
  6. 2016 (1)

More Years

Publications
  1. Journal of Nuclear Medicine (34)
  2. Journal of Clinical Oncology (5)
  3. European Journal of Nuclear Medicine (4)
  4. AIP Conference Proceedings (3)
  5. Clinical Positron Imaging (3)
  6. Medical Physics (3)

More Publications

Publishers
  1. Society of Nuclear Medicine (34)
  2. American Society of Clinical Oncology (5)
  3. Elsevier Inc. (5)
  4. Springer Verlag (4)
  5. American Association of Physicists in Medicine (3)
  6. American Institute of Physics (3)

More Publishers

Results (70)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • [(18)F]TFB PET/CT misses intense [(124)I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer
    Journal Article

    Backhaus, P.; Pentlow, K. S.; Ho, A. L.; Mauguen, A.; Fagin, J. A.; Pillarsetty, N. V. K.; Lyashchenko, S. K.; Burnazi, E.; Ghossein, R. A.; Chhabra, S.; more...
    EJNMMI Research (2024)

    Fulltext@MSK | Save
  • Prospective comparison of F-18-TFB and I-124 PET/CT in metastatic thyroid cancer
    Meeting Abstract

    Backhaus, P.; Pentlow, K.; Ho, A.; Mauguen, A.; Fagin, J.; Pillarsetty, N. V. K.; Lyashchenko, S.; Abusamra, M.; Larson, S.; Schoder, H.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Prospective comparison of F-18-TFB and I-124 PET/CT in metastatic thyroid cancer
    Meeting Abstract

    Backhaus, P.; Pentlow, K.; Ho, A. L.; Mauguen, A.; Fagin, J. A.; Pillarsetty, N. V. K.; Lyashchenko, S. K.; Burnazi, E.; Ghossein, R. A.; Chhabra, S.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2023)

    Fulltext@MSK | Save
  • Radioimmunoscintigraphy and pretreatment dosimetry of (131)I-omburtamab for planning treatment of leptomeningeal disease
    Journal Article

    Pandit-Taskar, N.; Grkovski, M.; Zanzonico, P. B.; Pentlow, K. S.; Modak, S.; Kramer, K.; Humm, J. L.
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446)
    Meeting Abstract

    Burman, B.; Tuttle, R. M.; Grewal, R. K.; Sherman, E. J.; Baxi, S. S.; Boucai, L.; Sabra, M.; Fish, S.; Pentlow, K. S.; Haque, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ERBB3 monoclonal antibody CDX-3379: Results of a pilot clinical trial
    Journal Article

    Tchekmedyian, V.; Dunn, L.; Sherman, E.; Baxi, S. S.; Grewal, R. K.; Larson, S. M.; Pentlow, K. S.; Haque, S.; Tuttle, R. M.; Sabra, M. M.; more...
    Thyroid (2022)

    Fulltext@MSK | Save
  • Optimizing reconstruction parameters for quantitative (124)I-PET in the presence of therapeutic doses of (131)I
    Journal Article

    Fanchon, L. M.; Beattie, B. J.; Pentlow, K.; Larson, S. M.; Humm, J. L.
    EJNMMI Physics (2021)

    Fulltext@MSK | Save
  • Biodistribution and dosimetry of intraventricularly administered (124)I-omburtamab in patients with metastatic leptomeningeal tumors
    Journal Article

    Pandit-Taskar, N.; Zanzonico, P. B.; Kramer, K.; Grkovski, M.; Fung, E. K.; Shi, W.; Zhang, Z.; Lyashchenko, S. K.; Fung, A. M.; Pentlow, K. S.; more...
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers
    Journal Article

    Dunn, L. A.; Sherman, E. J.; Baxi, S. S.; Tchekmedyian, V.; Grewal, R. K.; Larson, S. M.; Pentlow, K. S.; Haque, S.; Tuttle, R. M.; Sabra, M. M.; more...
    Journal of Clinical Endocrinology and Metabolism (2019)

    Fulltext@MSK | Save
  • Enhancing radioiodine (RAI) incorporation into BRAF(V600E)-mutant, RAI-refractory thyroid cancers with the BRAF inhibitor vemurafenib: A pilot study
    Meeting Abstract

    Dunn, L.; Sherman, E. J.; Baxi, S. S.; Grewal, R. K.; Pentlow, K. S.; Haque, S.; Tuttle, R. M.; Sabra, M.; Fish, S.; Boucai, L.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save